Skip to main content

Animations

MJFF Publications

4361 - 4370 of 9038 Results
Title
Year
  • Year
  • 2024
  • 2024
  • 2024
  • 2025
  • 2024
  • 2025
  • 2025
  • 2024
  • 2025
  • 2025
  • Summary Details
    OPEN
    Title: Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
    Journal Name: Cell Death & Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41419-024-06534-8
    Citation Count: 7
  • Summary Details
    OPEN
    Title: RedOx regulation of LRRK2 kinase activity by active site cysteines
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-024-00683-5
    Citation Count: 7
  • Summary Details
    OPEN
    Title: An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-024-00723-x
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Seeding-competent early tau multimers are associated with cell type-specific transcriptional signatures
    Journal Name: Acta Neuropathologica
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s00401-025-02869-4
    Citation Count: 3
  • Summary Details
    OPEN
    Title: APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-024-07185-7
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Tet2 loss and enhanced ciliogenesis suppress α-synuclein pathology
    Journal Name: Acta Neuropathologica Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1186/s40478-025-01988-z
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Alpha-synuclein knockout impairs melanoma development and alters DNA damage repair in the TG3 mouse model in a sex-dependent manner
    Journal Name: Frontiers in Oncology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fonc.2025.1554059
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Elevated cholesterol is a common phenotype for dominant and recessive ATAD3-associated disorders
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1093/brain/awae402
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson’s disease
    Journal Name: Cell Reports Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.xcrm.2025.101999
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Cocreating the Visualization of Digital Mobility Outcomes: Delphi-Type Process With Patients
    Journal Name: JMIR Formative Research
    Publisher: JMIR Publications Inc.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.2196/68782
    Best OA location URL: https://doi.org/10.2196/68782
    Citation Count: 2
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.